HBM Holdings (HBM Holdings) Debt-to-Equity : 0.55 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings Debt-to-Equity?

HBM Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $37.43 Mil. HBM Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $28.58 Mil. HBM Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $119.99 Mil. HBM Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.55.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for HBM Holdings's Debt-to-Equity or its related term are showing as below:

HBMHF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04 Med: 0.05 Max: 0.98
Current: 0.55

During the past 6 years, the highest Debt-to-Equity Ratio of HBM Holdings was 0.98. The lowest was -0.04. And the median was 0.05.

HBMHF's Debt-to-Equity is ranked worse than
76.91% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs HBMHF: 0.55

HBM Holdings Debt-to-Equity Historical Data

The historical data trend for HBM Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings Debt-to-Equity Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.01

0.01

0.09

0.98

0.55

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial						0.09	0.39	0.98	0.83	0.55

Competitive Comparison of HBM Holdings's Debt-to-Equity

For the Biotechnology subindustry, HBM Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where HBM Holdings's Debt-to-Equity falls into.

HBM Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

HBM Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(37.434	+	28.578)	/	119.988
	=	0.55

HBM Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(37.434	+	28.578)	/	119.988
	=	0.55

HBM Holdings (OTCPK:HBMHF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

HBM Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of HBM Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024